Biomarkers May Identify Risk for Preeclampsia in Lupus Pregnancies
Thursday, November 8, 2007
Measuring levels of circulating antiangiogenic factors—soluble fms-like tyrosine kinase 1 (sFlt 1) and soluble endoglin (sEng)—may help identify which patients with systemic lupus erythematosus (SLE) and/or antiphospholipid antibodies (APLA) will develop preeclampsia. The researchers suggest that an angiogenic imbalance early in pregnancy increases the vulnerability to triggers of preeclampsia, according to data from the PROMISSE Study (Predictors of pRegnancy Outcome: bioMarkers In antiphospholipid antibody Syndrome and Systemic lupus Erythematosus) presented at the American College of Rheumatology meeting in Boston.
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms